TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01052246
Drug: Fixed combination of clindamycin 1% + benzoyl peroxide 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
Study: NCT00288262
Drug: melatonin 0.5 mg
Normalized name: melatonin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03081247
Drug: BGF 320/14.4/9.6 µg MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
Study: NCT00057408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03665779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
Study: NCT04506645
Drug: REGN5381
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose REGN5381 administered via IV infusion
Study: NCT03081247
Drug: BFF 320/9.6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
Study: NCT00384774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as intravenous infusion
Study: NCT02550743
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02550743
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02361034
Drug: GRC 27864
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02361034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02205372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00567203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02675647
Drug: Heparin, IV route, based on patients body weights (UI/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04238377
Drug: Multimodal Analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
Study: NCT03119948
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment
Study: NCT02116790
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take one 250mg Naproxen capsule
Study: NCT02116790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take two placebos.
Study: NCT01195948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule with no active ingredients to mimic B27PD
Study: NCT02616783
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study: NCT02616783
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/300 mg tablet administered orally once daily
Study: NCT02616783
Drug: Third agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG
Study: NCT00248651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
Study: NCT03119558
Drug: 18F-Florbetaben (Neuraceq®) PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
Study: NCT05225545
Drug: Sucrosomial Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Arm
Study: NCT05225545
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT02566044
Drug: QBW276
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg and 1.5 mg strengths
Study: NCT00794820
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m\^2 by vein over 60 minutes daily for 3 days (days 2-4)
Study: NCT03748134
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
Study: NCT03748134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
Study: NCT03106116
Drug: Standard medical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline- driven standard medical treatment for 7 weeks
Study: NCT04009603
Drug: Probiotic Agent
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit effects on the host.~Many clinical trials have been done on probiotic which show its use as a single or as an adjuvant drug therapy for various diseases with no or rare side effects. It is now frequently used agent for various diseases.~Apart from this many studies have been published related to effects of probiotics on PCOS, which shows effectiveness of probiotics when used for 8 to 12 weeks with no adverse effects observed by these micro-organisms but none of the study have compare it with standarad drug
Study: NCT00115310
Drug: NGX-4010
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03662126
Drug: KRT-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRT-232, administered by mouth
Study: NCT03662126
Drug: Best Available Therapy (BAT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best available therapy options include:~1. hydroxyurea~2. chemotherapy or~3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed).
Study: NCT01150630
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/mq/day per os for 14 days every 14 days for 6 months
Study: NCT02124811
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03690583
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 10 mg for children younger than 1 year old, 20 mg for children older than 1 year old, will be diluted in 1 ml of sterile water and administered orally every day in the morning during hospitalization
Study: NCT03226457
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
Study: NCT00477763
Drug: Restasis, Refresh Endura
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~2. Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening
Study: NCT03679013
Drug: Oral Gabapentin and Intravenous Acetaminophen (IV APAP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.
Study: NCT03679013
Drug: Opiate based pain regimen.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care opiate based pain regimen.
Study: NCT01591733
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to Eight-14 day cycles
Study: NCT02955953
Drug: LY2963016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01591733
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally, for 10 days
Study: NCT04165031
Drug: LY3499446
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03080740
Drug: Clindamycin palmitate hydrochloride dispersible tablet
Normalized name: Clindamycin Palmitate Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg, oral after meal, twice daily, a total of 7days
Study: NCT03794492
Drug: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Orally, up to 1g BID(total 2g daily)
Study: NCT03794492
Drug: Methylprednisolone/prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Methyprednisolone 500mg / Prednisolone 5mg
Study: NCT01718483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once-daily, orally, for up to 12 weeks
Study: NCT00904475
Drug: Lidoderm®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
Study: NCT01125631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 8 weeks (4 doses total)
Study: NCT00328861
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
Study: NCT02584283
Drug: Glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
Study: NCT02962310
Drug: Torrent's Rosuvastatin Calcium Tablets 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, crossover
Study: NCT02962310
Drug: Crestor 40 mg Tablets of AstraZeneca LP, USA
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, crossover
Study: NCT05366595
Drug: oral zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
Study: NCT02185417
Drug: Chlorthalidone (CTD)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
Study: NCT00984932
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg of rosuvastatin daily
Study: NCT04623866
Drug: Huaiqinhuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
Study: NCT00678418
Drug: VIVITROL® 380 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
Study: NCT00678418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
Study: NCT01500798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily
Study: NCT03555149
Drug: AB928
Normalized name: Adenosine A2a and A2b receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
Study: NCT01133548
Drug: Testosterone Gel 1.62%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 grams administered using an application Site Rotation
Study: NCT01133548
Drug: Testosterone Gel 1.62%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 grams administered using an a combination of Application sites
Study: NCT01948271
Drug: Trichuris Suis Ova
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
Study: NCT03303495
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
Study: NCT03303495
Drug: l-LV (dl-LV)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
Study: NCT02365727
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03826940
Drug: Lovastatin 60 MG
Normalized name: lovastatin 60 MG
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 MG Lovastatin per day for 3 consecutive days
Study: NCT03787459
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir plus placebos will be administrated from Days 1-7.
Study: NCT04021979
Drug: 1.5L PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume PEG
Study: NCT01342289
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.
Study: NCT03292016
Drug: APO-go
Normalized name: APO-Go
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous APO-go
Study: NCT03810183
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care
Study: NCT03810183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
Study: NCT01443858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
Study: NCT03487770
Drug: Placebo Oral Solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2\~15 mg/day (2\~15 mL/day)
Study: NCT01630135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, intranasal, 2 weeks
Study: NCT00306046
Drug: Bisphosphonate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02565316
Drug: Nepeta menthoides Boiss & Bohse freeze dried extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03826940
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 MG Placebo per day for 3 consecutive days
Study: NCT03563157
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: XELODA® tablets
Study: NCT01124318
Drug: Lactofiltrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
Study: NCT01124318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 tablets 3 times a day before meals during 21 days
Study: NCT04368507
Drug: YYB101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity~2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity
Study: NCT04576728
Drug: Trimodulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP will be administered via IV infusion on 5 consecutive days.
Study: NCT03563157
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide Capsules
Study: NCT03563157
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin Calcium
Study: NCT03200210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills manufactured to mimic Febuxostat tablets
Study: NCT01579513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
Study: NCT02417753
Drug: AZD9150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
Study: NCT03551847
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention involves not giving an infected patient antibiotics.
Study: NCT01406561
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
Study: NCT03502499
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of normal saline as an irrigant for open-irrigated ablation catheters
Study: NCT00933062
Drug: SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
Study: NCT00933062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
Study: NCT00636584
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03472053
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
Study: NCT02100046
Drug: Zarontin® (ethosuximide) and Stodal®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02551718
Drug: In Vitro Sensitivity-Directed Chemotherapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive personalized chemotherapy with one or more of the following drugs:~Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin
Study: NCT02662452
Drug: GLPG2222 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ascending doses, oral suspension
Study: NCT02662452
Drug: Placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: single doses, oral suspension, matching placebo
Study: NCT02662452
Drug: GLPG2222 multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple ascending doses, daily for 14 days, oral suspension
Study: NCT02662452
Drug: Placebo multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses, daily for 14 days, oral suspension, matching placebo
Study: NCT00176865
Drug: Campath 1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
Study: NCT00555074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, BID, oral route during 6 weeks
Study: NCT05002595
Drug: H. pylori eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agents for H. pylori eradication
Study: NCT00424281
Drug: Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability
Approvals — FDA: no, EMA: no, PMDA: no